Skip to main content
. 2021 Jun 11;11(6):545. doi: 10.3390/jpm11060545

Table 2.

Changes in Fugl–Meyer Assessment scores over time in the Cerebrolysin and placebo groups (full analysis set).

Parameter T0–T1 T1–T2 T0–T2
ΔFMA-T Cerebrolysin 11.0 ± 11.8 12.3 ± 13.4 * 23.3 ± 15.9
Placebo 13.8 ± 15.2 6.7 ± 10.5 20.5 ± 18.8
ΔFMA-UL Cerebrolysin 7.6 ± 8.7 8.2 ± 9.3 * 15.8 ± 12.6
Placebo 8.2 ± 11.0 4.4 ± 8.1 12.5 ± 13.3
ΔFMA-LL Cerebrolysin 3.3 ± 5.0 4.0 ± 6.0 7.4 ± 6.3
Placebo 5.6 ± 6.0 2.4 ± 4.8 8.0 ± 7.2

Values are means ± SDs; FMA-T, total Fugl–Meyer Assessment; FMA-UL, upper limb of FMA; FMA-LL, lower limb of FMA; * p < 0.05 compared with the placebo group.